Related Experiment Videos
Immunoregulation of lymphokine-activated killer cells
1Department of Pediatrics, University of Michigan, Ann Arbor 48109.
Clinical Immunology and Immunopathology
|October 1, 1988
Summary
Concanavalin A (Con A) and prednisolone (PRD) inhibit the generation and activity of lymphokine-activated killer (LAK) cells. These immune-modulating agents suppress LAK cell function, indicating active immunologic control over cytotoxic lymphocytes.
Area of Science:
- Immunology
- Cell Biology
Background:
- Lymphokine-activated killer (LAK) cells are crucial for cellular immunity.
- Understanding factors that modulate LAK cell function is vital for immunotherapy.
Purpose of the Study:
- To investigate the in vitro effects of Concanavalin A (Con A) and prednisolone (PRD) on LAK cell cytotoxicity and generation.
- To elucidate the immunomodulatory mechanisms of Con A and PRD on LAK cells.
Main Methods:
- In vitro assessment of LAK cell cytotoxic functions using a 51Cr release assay.
- Evaluation of LAK cell generation and lytic capacity upon incubation with Con A or PRD.
- Dose-response analysis of Con A and PRD effects on LAK cell activity.
Main Results:
- Con A did not significantly affect direct LAK cell cytotoxicity but suppressed LAK cell generation and lytic capacity in a dose-dependent manner.
- PRD decreased both the numbers and activity of LAK cells across various target cells.
- Neither Con A nor PRD pretreatment altered target cell sensitivity to LAK-mediated lysis.
Conclusions:
- Con A and PRD inhibit LAK cell generation and directly impair their cytotoxic activity.
- LAK cells, similar to other cytotoxic cells, are subject to active immunologic regulation.
- These findings highlight the potential of Con A and PRD as modulators of cellular immune responses.